The national drug procurement with volume has entered the era of "big merger" competition!

Every year is similar, but every year is different
.

On January 28 this year, the General Office of the State Council issued the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs" (Guobanfa [2021] No.

In November 2019, the State Council's Leading Group for Deepening the Reform of the Medical and Health System issued the "Several Policy Measures on Further Deepening the Reform of the Medical and Health System with the Centralized Procurement and Use of Medicines as a Breakthrough" (Guoyugaifa [2019] No.
3, referred to as "Measures") In fact, the tune has been set for the three years 2020-2022
.

"Measures" requirements: From 2020 to 2022, all localities should seize the window period for pilot reduction of drug prices and the addition of consumables, and conduct annual price adjustment assessments, and adjust prices in a steady and orderly manner if the starting conditions are met, and increase the dynamic adjustment of medical service prices In principle, the increased costs due to price adjustments are included in the scope of medical insurance payment

The author’s first reaction to the relevant content at the time was that these three years will be the key three years for the development of centralized drug procurement: in 2019, local mass procurement has not yet taken shape, 2020 is still in the initial stage of exploration, and 2022 is the end of the year.
2021 is the main year for the national drug procurement to land in succession
.

Facts have proved that so far, the understanding is still basically accurate

Document No.
2 requires exploring the merger of different generic drugs with similar indications or functions and indications to carry out centralized and high-volume procurement
.

In particular, the author understands that this starting point is more for proprietary Chinese medicines whose procurement rules are not clear

At present, there have been four major mergers and competitions
.

They are: Fujian, Jilin, Shanghai, and Guangdong

1.
Fujian

1.
Fujian

In 2017, Fujian Sunshine Procurement has conducted a combined group bidding for some products in the same therapeutic field during the tenth bid (pictured):

Source: Official website of Fujian Medical Insurance Bureau: Fengqing

2.
Jilin

2.
Jilin

On May 28 this year, the Jilin Provincial Recruitment and Procurement Official issued a notice to list drugs with the same or similar chemical active ingredients as the fourth batch of national organizations and the "six provinces and two districts" selected on the Jilin Province public resource trading platform.
To be announced, the relevant companies involved are required to proactively declare the national minimum bid-winning (online) price (including the prices of Chongqing, Guangdong, and Fujian) of the relevant drugs at the national level
.

According to the author's statistics, a total of 891 product regulations were involved this time

Source: Jilin Province Public Resources Trading Center (Compilation: Fengqing)

3.
Shanghai

3.
Shanghai

On June 7, the Office of the Shanghai Public Medical Institutions (Part of) Drug Centralized Bargaining Purchasing Alliance issued an announcement to organize the Shanghai Public Medical Institutions (Part of) Drug Centralized Bargaining Purchasing Alliance Drug Group Procurement and Centralized Bargaining Work
.

In the group procurement documents, the review method particularly emphasizes the requirements for classification review, namely:

Western medicine is reviewed according to the anatomical-treatment-chemical classification (ATC) and route of administration
.

Proprietary Chinese medicines are reviewed according to the classification of functions and indications and the route of administration
.

Chemical drugs are reviewed according to the anatomical-treatment-chemical classification (ATC) and the route of administration
.

If classified according to this approach, the scope of the classification will be greatly expanded

Finishing: wind light

Chinese patent medicines, the Shanghai GPO will be reviewed according to the classification of functions and indications and the route of administration
.

The author tried to classify through the medical insurance catalog as follows:

Finishing: wind light

Four, Guangdong

Four, Guangdong

According to relevant information circulating in the market, the Guangdong Volume Procurement Alliance has implemented a mechanism for introducing varieties in the same therapeutic area for under-competitive varieties in accordance with the requirements of the same therapeutic area
.
Try to merge the varieties by merging functional indications or indications to achieve full competition
.

to sum up

to sum up

In general, from Fujian in 2017 to Jilin, Shanghai and Guangdong in 2021, in-depth exploration of the combined procurement of different generic drugs with similar indications or functions and indications has become a fact that pharmaceutical and industrial enterprises have to face
.
Under the new situation, the overall idea of ​​mass procurement is to make every effort to promote competition, ensure quality and supply, create a fair competitive market environment, guide the transformation of enterprise competition into product quality and cost competition, and promote the healthy development of enterprises
.
For enterprises, only by improving quality, increasing revenue and reducing expenditure, strictly controlling costs, and improving operations can they calmly embrace the new era of centralized drug procurement
.